ACR Convergence 2023| ANCA-Associated Vasculitis| Psoriatic Arthritis

An official publication of the ACR and the ARP serving rheumatologists and rheumatolgy professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • ACR Open Rheumatology
    • Arthritis & Rheumatology
    • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Myositis

Myositis Autoantibodies as Biomarkers

Lara C. Pullen, PhD  |  June 4, 2019

A recent study details the autoantibodies of patients with myositis, confirming most patients carry these antibodies. The results also describe how myositis-specific autoantibodies can be used to identify distinct clinical subsets of idiopathic inflammatory myopathy…

Pregnancy Outcomes in Women with Idiopathic Inflammatory Myositis

Lara C. Pullen, PhD  |  April 8, 2019

New data from India suggest women with idiopathic inflammatory myositis are at increased risk of poor fetal outcomes and spontaneous abortions. In the study, researchers found these women had worse obstetric outcomes and increased risk of fetal complications…

Cancer-Associated Myositis: A Case Report & Review of the Literature

Cancer-Associated Myositis: A Case Report & Review of the Literature

Osman Bhatty, MD, Rouhin Sen, MD, & Joseph Nahas, MD  |  February 17, 2019

Since it was first reported in 1916, a correlation between inflammatory myopathies and cancer has been noted in several studies. Population studies have confirmed this relationship, and the phrase cancer-associated myopathy has entered the vernacular. Over the past decade, research efforts have shifted toward revealing associations between autoantibodies and clinical phenotypes. One subset of auto-antigens…

Immune Checkpoint Inhibitors & Immune-Related Adverse Events

Priya Chokshi, MD, Roberta Seidman, MD, Noah Levit, PhD, MD, & Steven E. Carsons, MD  |  September 20, 2018

Immune checkpoint inhibitors (ICIs) are at the forefront of advances in cancer therapy and have shown promising results for progression-free survival. Checkpoint signaling pathways, such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1), normally regulate the immune response to promote self-tolerance and prevent tissue damage and inflammation. PD-1 is a…

Promising Avenues in Myositis: Research Targets Disease Specificity

Thomas R. Collins  |  September 10, 2018

AMSTERDAM—Research in myositis treatments is beginning to find its way, with investigators pursuing avenues special to the disease so therapy for patients may no longer involve piggybacking on existing treatments for other illnesses, an expert said at EULAR: the Annual European Congress of Rheumatology. “Finally, in myositis there are targets being investigated that are more…

Statins Linked to Idiopathic Inflammatory Myositis

Will Boggs, MD  |  July 31, 2018

NEW YORK (Reuters Health)—Statin use is associated with an increased likelihood of developing idiopathic inflammatory myositis (IIM), researchers from Australia report. “[Although] the incidence of IIM is rare, with the increasing use of statins worldwide and the severity of this condition, this study highlights the need for increased awareness of the condition and the importance…

Managing Myositis in 3 Different Scenarios

Susan Bernstein  |  February 18, 2018

SAN DIEGO—In Hot Topics in Myositis, a session held Nov. 7 at the 2017 ACR/ARHP Annual Meeting, rheumatologists discussed treating myositis patients in three different clinical scenarios: persistently elevated creatine kinase (CK), immune-mediated necrotizing myopathies and lung disease. Elevated CK Patients with persistently elevated levels of CK enzyme and normal muscle strength “may still have…

Intriguing Patient Cases Presented at the ACR Annual Meeting Thieves Market

Susan Bernstein  |  February 17, 2018

SAN DIEGO—At the 2017 Thieves Market, held Nov. 6 at the ACR/ARHP Annual Meeting, rheumatologists from around the world presented patient cases to an audience of colleagues, who then voted via text messaging to choose the cases they felt were most perplexing or intriguing. The winner received a free 2018 Annual Meeting registration, and the…

Fellows’ Forum Case Report: Progressive Weakness and Debilitation with Skin Rash

Usman T. Malik, MBBS  |  December 19, 2017

The Presentation A pale, quiet woman—her mother—wheeled the girl into my clinic. It was a blistering Florida day, and the girl was shivering. She glanced up at me when I said hello and asked her name. “Hi,” she said, giving me a broad smile. Her smile was the only broad thing about her. Her elbows…

Autoantibodies in Autoimmune Myopathy

Autoantibodies in Autoimmune Myopathy

Ruth Jessen Hickman, MD  |  September 18, 2017

In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2000-2023 American College of Rheumatology. All rights reserved. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences